The UAE has made a global healthcare milestone by becoming the first country to authorise an oral medicine for eligible patients with non-segmental vitiligo, offering a new treatment option.
UAE Leads Globally With First Approval of Oral Treatment for Non-Segmental Vitiligo.
The once-daily oral medication is approved for adults and adolescents aged 12 years and older whose non-segmental vitiligo is extensive or severe enough to require treatment that works throughout the body.
UAE approves new oral treatment for non-segmental vitiligo
The UAE has achieved a notable milestone in dermatological care by becoming the first country to approve an oral medicine specifically for the treatment of non-segmental vitiligo. The regulatory decision introduces another potential treatment option for eligible patients aged 12 and above who require systemic therapy.
The approval was granted by the Emirates Drug Establishment (EDE) for an additional therapeutic use of RINVOQ, whose active ingredient is upadacitinib. The authorisation covers adults and adolescents aged 12 years and older who have non-segmental vitiligo and whose condition requires medication that works systemically rather than only on the affected areas of the skin.
This development marks an important addition to the treatment options available to people living with vitiligo in the UAE. It is particularly relevant to patients whose condition is extensive or who, following medical assessment, are considered suitable candidates for systemic treatment.
RINVOQ is an oral medicine taken once a day. Its newly approved use gives eligible patients access to a treatment that works throughout the body, rather than being applied directly to individual areas where pigment has been lost.
What is vitiligo?
Vitiligo is a long-term skin condition characterised by the loss of pigmentation in certain areas of the body. People with the condition develop lighter or white patches because the cells responsible for producing skin pigment, known as melanocytes, are damaged or destroyed.
Melanocytes produce melanin, the natural pigment that determines much of the colour of a person’s skin, hair and eyes. When these cells stop functioning or are lost in a particular area, the affected skin can gradually become lighter.
The condition can appear on almost any part of the body. Commonly affected areas include the face, hands, arms and other visible parts of the skin. In some cases, pigmentation can also be lost around the mouth and eyes or in areas exposed to repeated friction.
Vitiligo affects people differently. Some individuals may develop only a few small patches, while others can experience more widespread changes in pigmentation.
The condition can also change over time. New areas of depigmentation may appear, while existing patches can become larger.
Non-segmental vitiligo
The UAE approval specifically relates to non-segmental vitiligo, a form of the condition that can affect multiple parts of the body.
Non-segmental vitiligo is generally characterised by patches that can appear on both sides of the body. The distribution may be relatively symmetrical, although the exact pattern varies from person to person.
The disease can remain stable in some individuals, while in others it may gradually progress.
Because non-segmental vitiligo can affect larger or multiple areas of the body, some patients may require treatment that works beyond individual skin patches.
This is where systemic medicines can become relevant. Instead of being applied only to the skin, systemic therapies are taken in a way that allows the medicine to act throughout the body.
Who is covered by the new approval?
The EDE’s decision applies to adults and adolescents aged 12 years and older with non-segmental vitiligo who require systemic treatment.
The approval does not mean that every person with vitiligo will automatically be prescribed RINVOQ.
Doctors generally consider a number of factors before recommending systemic therapy, including the extent of the condition, how active it is, the patient’s age and overall health, medical history and other medicines they may be taking.
For adolescents, healthcare professionals will also consider age-specific medical factors before deciding whether the treatment is appropriate.
Patients with vitiligo should therefore seek advice from a qualified dermatologist or healthcare professional rather than attempting to determine their own treatment requirements.
How the medicine differs from topical treatment
Many treatments for skin conditions are applied directly to the affected area.
An oral systemic medicine works differently because it is taken by mouth and acts within the body.
This distinction can be particularly relevant when a condition affects several areas of the skin or when a physician determines that a systemic approach is appropriate.
The UAE’s approval of RINVOQ gives eligible patients another option that can be considered as part of a dermatologist-led treatment plan.
The medicine’s active ingredient, upadacitinib, belongs to a class of medicines known as Janus kinase, or JAK, inhibitors.
These medicines work by interfering with specific pathways involved in immune-system signalling.
The role of the immune system
The precise cause of vitiligo has not been completely established.
However, researchers believe that the immune system plays an important role in many cases.
In autoimmune conditions, the body’s immune response mistakenly targets its own cells or tissues.
In vitiligo, this immune activity is believed to contribute to the destruction or loss of melanocytes.
As melanocytes disappear, the affected areas lose their ability to produce normal amounts of melanin, resulting in lighter patches of skin.
The understanding of these biological mechanisms has helped researchers investigate treatments that target immune pathways.
Upadacitinib is one such medicine. Its activity involves blocking specific JAK pathways that participate in immune signalling.
The approval for non-segmental vitiligo therefore represents a move towards treatments designed to influence biological mechanisms associated with the disease.
Vitiligo is not contagious
Despite being visible on the skin, vitiligo is not an infectious disease.
It cannot be transmitted from one person to another through touching, sharing personal items or normal social contact.
This is an important distinction because misunderstandings about visible skin conditions can sometimes lead to unnecessary social stigma.
People with vitiligo can safely interact with others without posing an infection risk.
The condition is also not caused simply by poor hygiene.
More than a change in appearance
Although vitiligo primarily affects skin pigmentation, its impact can extend beyond physical appearance.
Visible changes to the skin can affect how people feel about themselves, particularly when patches appear on highly noticeable parts of the body.
Some patients may experience embarrassment, anxiety or reduced confidence because of the condition.
Concerns can be particularly significant for teenagers, who may already be sensitive about their appearance and how they are perceived by classmates and peers.
For adults, visible depigmentation may also affect social interactions and emotional wellbeing.
This means that managing vitiligo can involve more than attempting to restore pigmentation. Healthcare professionals may also need to consider the psychological and social impact of the condition.
Why the UAE approval matters
The UAE’s decision represents an important development in the country’s approach to innovative medical treatments.
By approving a systemic oral therapy for eligible non-segmental vitiligo patients, the regulator has expanded the range of treatment options available to people living with the condition.
The decision also places the UAE at the forefront of regulatory developments in vitiligo treatment.
For patients who have been looking for additional therapeutic options, the approval could provide another avenue to discuss with their doctors.
However, regulatory approval should not be interpreted as a guarantee that the treatment will work in the same way for every patient.
Response to therapy can vary, and doctors need to assess the individual circumstances of each person before prescribing medication.
Importance of medical guidance
People experiencing new or unexplained changes in skin pigmentation should seek professional medical advice.
A dermatologist can examine the affected areas and determine whether the changes are consistent with vitiligo or another skin condition.
Once a diagnosis has been established, the doctor can discuss available management strategies.
For people with confirmed non-segmental vitiligo, the choice of treatment can depend on the extent and location of pigmentation loss, how quickly the condition is changing and the individual’s overall health.
The newly approved medicine may be considered for patients who meet the relevant criteria for systemic treatment.
Patients should not start or stop prescription medication without consulting their healthcare provider.
What the new approval means for adolescents
The inclusion of patients aged 12 and above is particularly notable because vitiligo can also affect younger people.
Adolescence can be a challenging period for anyone dealing with a visible skin condition.
Changes in appearance may influence confidence, social interactions and emotional wellbeing during a stage of life when young people can be particularly conscious of how they look.
Having an additional medically approved treatment option may therefore be significant for eligible adolescents and their families.
Nevertheless, treatment decisions for younger patients require careful assessment.
Doctors must consider the potential benefits alongside safety considerations and the patient’s individual circumstances.
Parents and teenagers should discuss all available options with an appropriate healthcare professional.
A broader development in vitiligo research
The approval comes as research into vitiligo continues to expand.
Scientists have increasingly focused on understanding the immune mechanisms that contribute to melanocyte destruction.
This research has encouraged the development of medicines designed to influence specific immune pathways rather than relying exclusively on conventional approaches.
RINVOQ’s approval for non-segmental vitiligo reflects this broader shift in the treatment landscape.
The medicine is already used for other inflammatory and immune-related conditions, and its use in vitiligo represents an additional application of its mechanism of action.
The development highlights how a better understanding of disease biology can lead to new treatment possibilities.
A new option, not a universal solution
The UAE approval should be viewed as the introduction of another treatment choice rather than a universal solution for vitiligo.
The condition varies considerably between individuals.
Some patients may have limited areas of pigmentation loss, while others may experience widespread involvement.
The course of the disease can also differ significantly.
For this reason, there is no single treatment approach that is suitable for everyone.
Doctors may consider different therapies depending on the patient’s needs, and systemic treatment may be appropriate only for certain individuals.
The new approval provides physicians with another tool when evaluating patients who require treatment that acts throughout the body.
Understanding systemic therapy
Systemic therapy refers to treatment that is absorbed into the body and can have effects beyond one specific area.
This differs from topical medicines, which are generally applied directly to the skin.
For patients with extensive non-segmental vitiligo, a systemic approach may be considered when a dermatologist believes that treating the condition more broadly is appropriate.
The EDE’s approval specifically establishes the authorised use of RINVOQ for eligible patients in this category.
The once-daily oral format may also offer a different treatment experience compared with therapies that require repeated topical application.
Nevertheless, convenience is only one consideration when selecting treatment. Safety, medical suitability and expected benefits remain central to the decision.
The importance of accurate information
As new treatments become available, patients may encounter considerable information about them online.
It is important to distinguish between regulatory approval, clinical evidence and individual treatment recommendations.
Approval means that the relevant health authority has authorised the medicine for a specified medical use under defined conditions.
It does not mean that every patient with the condition is suitable for the medicine.
Patients should rely on their dermatologist and official medical information when deciding whether a treatment is appropriate.
UAE’s role in healthcare innovation
The approval also highlights the UAE’s growing focus on providing access to advanced medical therapies.
The Emirates Drug Establishment is responsible for regulating medicines and pharmaceutical products in the country.
Its decision to authorise the new indication reflects the regulatory assessment of the medicine for the specified patient group.
For the UAE’s healthcare sector, such approvals can help expand treatment choices while supporting the country’s broader ambitions in medical innovation.
For patients, the most immediate significance is practical: eligible people with non-segmental vitiligo now have another treatment option that they can discuss with their healthcare providers.
What patients should know
People living with vitiligo should remember that the condition is not contagious and is not something that can be passed to other people.
The appearance of white patches can be concerning, but the condition itself is not an infection.
Anyone noticing changes in skin pigmentation should obtain a professional diagnosis before starting treatment.
For those diagnosed with non-segmental vitiligo, treatment decisions should be made together with a qualified medical professional.
The newly authorised oral medicine may be an option for adults and adolescents aged 12 and above whose condition meets the criteria for systemic therapy.
Whether it is appropriate will depend on the patient’s individual medical circumstances.
A significant step for vitiligo care
The UAE’s approval of RINVOQ for non-segmental vitiligo represents a notable development in the treatment of a condition that can affect both physical appearance and emotional wellbeing.
The decision makes an oral systemic therapy available to eligible patients aged 12 and older, giving dermatologists another option when managing non-segmental vitiligo.
It also reflects growing scientific interest in treatments that target immune pathways believed to contribute to the destruction of melanocytes.
While the approval does not mean that vitiligo can be treated in exactly the same way for every patient, it expands the possibilities available to those who need systemic therapy.
For patients and families, the development offers another reason to seek specialist advice and discuss the latest evidence-based options.
Ultimately, the most appropriate treatment will depend on the individual’s condition, medical history and response to therapy. The new UAE approval adds another tool to that conversation, while reinforcing the country’s position at the forefront of access to emerging treatments for non-segmental vitiligo.
New oral option expands treatment choices for vitiligo patients
The UAE’s latest regulatory decision marks an important development in the management of non-segmental vitiligo, as eligible patients now have access to an oral systemic medicine as part of the country’s approved treatment options.
The approval introduces a different approach for patients whose condition requires therapy that works throughout the body. Rather than being applied directly to affected areas, the newly authorised treatment is taken orally, offering an additional option for people who meet the relevant medical requirements.
RINVOQ (upadacitinib) is administered once a day and has received approval in the UAE for the treatment of eligible adults and adolescents aged 12 years and above with non-segmental vitiligo who require systemic therapy.
The authorisation does not mean that the medicine is suitable for every person diagnosed with vitiligo. Treatment decisions remain dependent on an individual’s medical condition, disease pattern, overall health and the assessment of a qualified healthcare professional.
Vitiligo can appear in different areas
Vitiligo is characterised by the loss of normal skin pigmentation, resulting in lighter or white areas appearing on the body.
The condition can develop in a variety of locations, including areas that are highly visible. Patches may appear on the face, hands, arms, legs and other parts of the body.
The appearance of vitiligo can vary considerably between individuals. Some people may develop relatively small areas of depigmentation, while others can experience more widespread changes.
The condition may also progress differently from one person to another. In some cases, patches remain stable for extended periods, while in others, additional areas may develop over time.
Because of these differences, treatment cannot be approached in exactly the same way for every patient.
Why diagnosis matters
Although white or lighter patches are a characteristic sign of vitiligo, not every change in skin colour is necessarily caused by the condition.
A number of other skin disorders can produce changes in pigmentation or cause areas of skin to appear lighter.
For this reason, people who notice unexplained changes in their skin should not attempt to diagnose themselves based solely on appearance.
A dermatologist or other qualified medical professional can examine the affected areas and determine the likely cause.
Accurate diagnosis is important because treatment depends on what is causing the pigmentation change.
If the condition is confirmed as vitiligo, a specialist can then assess its type, distribution and extent before discussing possible management strategies.
Different treatment approaches
Treatment for vitiligo can vary according to the individual’s circumstances.
Existing approaches may include medicines applied directly to the skin, light-based therapies and other procedures.
Topical treatments are generally used on affected areas and may be considered when the extent and location of the condition make this approach suitable.
Phototherapy is another established option. It involves carefully controlled exposure to specific wavelengths of light under medical supervision.
For some patients, laser-based approaches or other specialist procedures may also be considered depending on the nature and distribution of the condition.
The availability and suitability of each treatment can vary, which is why a dermatologist’s assessment remains important.
Why systemic treatment is different
Systemic medicines differ from treatments that are applied only to individual patches.
An oral systemic treatment is absorbed into the body and can act through biological pathways throughout the system.
This type of therapy may be particularly relevant for patients whose non-segmental vitiligo affects several areas or whose condition requires a broader treatment approach.
The new UAE approval provides doctors with another option when considering systemic therapy for eligible patients.
However, systemic medicines can have specific safety considerations and are not necessarily appropriate for everyone.
Patients should therefore discuss the potential benefits, risks and suitability of treatment with their healthcare provider.
A once-daily treatment
One of the key features of the newly approved therapy is its oral format.
RINVOQ is taken once daily, providing an alternative to treatments that require direct application to the skin.
For patients who qualify for systemic therapy, having an oral option may broaden the range of approaches that can be considered during treatment discussions.
The medicine’s active ingredient, upadacitinib, belongs to a class known as JAK inhibitors.
These medicines target specific pathways involved in immune-system signalling.
The role of the immune system is particularly relevant to vitiligo because researchers believe that immune activity contributes to the destruction of melanocytes, the cells responsible for producing melanin.
Understanding the science behind the treatment
Melanocytes are specialised cells that produce melanin, the pigment responsible for much of the natural colour of the skin.
When melanocytes are damaged or destroyed, the affected skin can lose its pigmentation.
Vitiligo is widely considered to have an autoimmune component, although its precise causes are complex and not completely understood.
Researchers have therefore explored treatments that can influence immune responses involved in the condition.
Upadacitinib works by targeting certain JAK pathways involved in immune signalling.
The approval of RINVOQ for non-segmental vitiligo reflects the growing focus on therapies that address biological mechanisms associated with the disease.
The UAE’s regulatory role
The Emirates Drug Establishment said the approval demonstrates the country’s ability to respond to advances in medical research and pharmaceutical development.
The authority’s role includes evaluating and regulating medicines made available in the UAE.
The decision to approve a new indication for RINVOQ represents another example of the country’s efforts to expand access to innovative therapies where they meet the necessary regulatory requirements.
According to the EDE, the development also supports the UAE’s broader objectives of strengthening its pharmaceutical and healthcare sectors.
By keeping pace with developments in international medical research, regulators can provide patients with access to newer treatment options following the relevant assessment process.
Supporting pharmaceutical innovation
The approval is also part of the UAE’s wider efforts to develop a more advanced pharmaceutical environment.
The country has increasingly focused on attracting healthcare investment, supporting research and development and making innovative medicines available to patients.
Regulatory decisions play an important role in this process because new medicines and new uses for existing medicines must undergo appropriate assessment before they can be authorised.
For patients, this regulatory work can ultimately translate into a wider range of treatment possibilities.
The approval of RINVOQ for eligible non-segmental vitiligo patients therefore has significance beyond the medicine itself.
It demonstrates how developments in medical science can be incorporated into national healthcare systems.
Why specialist advice is important
The EDE has encouraged people who notice unusual changes in their skin colour to seek advice from a specialist.
This recommendation is particularly important because pigmentation changes can have several possible causes.
A healthcare professional can assess the appearance and distribution of the patches and determine whether additional examinations are necessary.
Once the diagnosis is established, the specialist can explain the available treatment options and determine which approach is most suitable.
This may include discussing topical therapy, phototherapy, systemic medication or other treatment strategies depending on the patient’s circumstances.
Treatment should be personalised
There is no single approach that works identically for everyone with vitiligo.
The extent of pigmentation loss, the locations affected, the speed at which the condition is changing and the patient’s age can all influence treatment decisions.
A person’s general health and medical history may also affect which medicines can safely be considered.
For adolescents, healthcare professionals must take particular care when assessing systemic treatment.
This is why the UAE approval should be understood as creating an additional option for eligible patients rather than recommending the medicine for everyone with vitiligo.
Visible symptoms can affect wellbeing
Although vitiligo is not contagious, its visible nature can sometimes have a significant emotional impact.
People with noticeable patches may experience concerns about their appearance or worry about how others perceive them.
This can be especially challenging when depigmentation affects the face, hands or other exposed parts of the body.
Children and teenagers may face particular difficulties because appearance and peer relationships can be important during adolescence.
Effective management of vitiligo can therefore involve more than addressing the physical symptoms.
Doctors may also consider how the condition affects a person’s quality of life when discussing treatment.
Darker skin can make contrast more noticeable
Vitiligo can occur in people of every skin tone.
However, the contrast between areas of normal pigmentation and depigmented patches may be more visually apparent in people with darker skin.
This can make the condition particularly noticeable and may increase concerns about appearance.
Despite these differences in visibility, the underlying condition remains the same: affected areas lose pigment because melanocytes are damaged or destroyed.
Anyone experiencing new areas of depigmentation should seek professional advice regardless of their skin tone.
Approval does not mean a cure
It is also important to distinguish between a new treatment approval and a cure for vitiligo.
The authorisation of RINVOQ provides another therapeutic option for a defined group of patients.
It does not mean that the condition has been eliminated or that every patient will experience the same treatment response.
Vitiligo is a complex condition and outcomes can differ between individuals.
Patients should therefore have realistic expectations and discuss likely benefits and possible risks with their dermatologist.
Patients should avoid self-treatment
Because vitiligo can resemble other causes of skin depigmentation, people should avoid relying on online images or self-diagnosis.
Using medicines without medical guidance can also be inappropriate, particularly when systemic treatments are involved.
A qualified specialist can determine whether treatment is required and, if so, identify the most appropriate option.
For patients who are candidates for RINVOQ, doctors can also provide guidance on how the medicine should be used and what monitoring may be necessary.
A broader milestone for UAE healthcare
The approval represents a significant addition to the UAE’s dermatology treatment landscape.
For eligible patients with non-segmental vitiligo who require systemic therapy, an approved once-daily oral medicine now provides another avenue to explore with their healthcare provider.
The decision also highlights the country’s focus on bringing new medical developments into its healthcare system.
By responding to advances in pharmaceutical science and expanding access to innovative therapies, the UAE aims to provide patients with more choices while maintaining regulatory oversight.
Early medical assessment remains important
The EDE’s recommendation for people to seek specialist advice when they notice unusual skin changes is therefore an important part of the announcement.
Early assessment does not necessarily mean that every patient will require medication.
Instead, it allows a healthcare professional to establish what is causing the pigmentation changes and determine whether treatment is appropriate.
For confirmed vitiligo cases, early and accurate evaluation can also help patients understand their condition and explore available management strategies.
What the new approval means for patients
For people living with non-segmental vitiligo, the UAE’s regulatory decision represents an expansion of the available treatment landscape.
RINVOQ’s once-daily oral format offers a systemic approach for eligible adults and adolescents aged 12 and older who require this type of therapy.
At the same time, patients should remember that treatment decisions remain individual.
The most appropriate therapy will depend on the characteristics of the condition and the patient’s overall medical circumstances.
The new approval does not replace existing treatment approaches such as topical medicines, phototherapy or other specialist options. Instead, it adds another possibility for doctors and eligible patients to consider.
Looking ahead
The development reflects continuing progress in understanding vitiligo and the biological mechanisms that contribute to melanocyte loss.
As researchers learn more about the role of immune pathways in the disease, newer therapies may provide additional ways of managing it.
The UAE’s decision to approve RINVOQ for eligible non-segmental vitiligo patients represents one step in that evolving treatment landscape.
For patients, the most important takeaway is that an additional approved option is now available, but it should be considered under professional medical guidance.
Anyone who notices unexplained white or lighter patches on their skin should consult a dermatologist rather than assuming the cause.
A proper diagnosis can help distinguish vitiligo from other conditions and ensure that treatment is selected according to the patient’s specific needs.
With the latest approval, the UAE has expanded access to systemic treatment for a defined group of people living with non-segmental vitiligo, while reinforcing its focus on medical innovation, regulatory development and access to emerging healthcare solutions.
